WO1993019750A1 - Composes efficaces dans le traitement de maladies allergiques ou inflammatoires - Google Patents

Composes efficaces dans le traitement de maladies allergiques ou inflammatoires Download PDF

Info

Publication number
WO1993019750A1
WO1993019750A1 PCT/US1993/002325 US9302325W WO9319750A1 WO 1993019750 A1 WO1993019750 A1 WO 1993019750A1 US 9302325 W US9302325 W US 9302325W WO 9319750 A1 WO9319750 A1 WO 9319750A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclohexan
alkyl
formula
methoxyphenyl
cyano
Prior art date
Application number
PCT/US1993/002325
Other languages
English (en)
Inventor
Siegfried Benjamin Christensen, Iv
Paul Elliot Bender
Cornelia Jutta Forster
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP51746793A priority Critical patent/JP3192424B2/ja
Priority to DE69330459T priority patent/DE69330459T2/de
Priority to AT93907493T priority patent/ATE203159T1/de
Priority to DK93907493T priority patent/DK0636025T3/da
Priority to EP93907493A priority patent/EP0636025B1/fr
Priority to CA002133337A priority patent/CA2133337C/fr
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to MA23147A priority patent/MA22858A1/fr
Priority to SI9300168A priority patent/SI9300168A/sl
Publication of WO1993019750A1 publication Critical patent/WO1993019750A1/fr
Priority to US08/488,556 priority patent/US5811455A/en
Priority to HK98113532A priority patent/HK1012262A1/xx
Priority to GR20010401717T priority patent/GR3036853T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/757—Unsaturated compounds containing a keto groups being part of a ring containing —CHO groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C07C45/515—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an acetalised, ketalised hemi-acetalised, or hemi-ketalised hydroxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/47—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to novel compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).
  • TNF Tumor Necrosis Factor
  • Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli. Identification of novel therapeutic agents for asthma is made difficult by the fact that multiple mediators are responsible for the development of the disease. Thus, it seems unlikely that eliminating the effects of a single mediator will have a substantial effect on all three components of chronic asthma.
  • An alternative to the "mediator approach” is to regulate the activity of the cells responsible for the pathophysiology of the disease. One such way is by elevating levels of cAMP (adenosine cyclic 3',5'- monophosphate).
  • Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs Endocrinology Proceedings of the 4th International Congress Excerpta Medica, 17-29, 1973], When the appropriate agonist binds to specific cell surface receptors, adenylate cyclase is activated, which converts Mg + 2-ATP to cAMP at an accelerated rate.
  • Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma.
  • an elevation of cAMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of onocyte and macrophage activation.
  • compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells.
  • the principal cellular mechanism for the inactivation of cAMP is hydrolysis of the 3'-phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs).
  • PDE IV cyclic nucleotide phosphodiesterase
  • PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo.
  • PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated.
  • Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
  • the compounds of this invention also inhibit the production of Tumor Necrosis
  • TNF Tumor Factor
  • rheumatoid arthritis rheumatoid spondylitis
  • osteoarthritis gouty arthritis and other arthritic conditions
  • sepsis septic shock, endotoxic shock, gram negative sepsis
  • toxic shock syndrome adult respiratory distress syndrome
  • cerebral malaria chronic pulmonary inflammatory disease
  • silicosis pulmonary sarcoidosis
  • bone resorption diseases reperfusion injury, graft vs.
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to human acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis, in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis.
  • AIDS acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis ulcerative colitis
  • pyresis in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis.
  • HIV Human Immunodeficiency Virus
  • HIV-1 HIV-1
  • HIV- 2 HIV-2
  • HIV-3 HIV-3
  • HIV entry into the T lymphocyte requires T lymphocyte activation.
  • Viruses such as HTV-1 or HIV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HTV gene expression and/or HIV replication.
  • C-ytoldnes are implicated in activated T-cell-mediated HTV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by inhibition of cytokine production, notably TNF, in an HIV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HTV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HTV infection.
  • Monocytes, macrophages, and related cells, such as kupffer and glial cells have also been implicated in maintenance of the EQV infection.
  • T cells like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells.
  • Monokines such as TNF, have been shown to activate HTV replication in monocytes and/or macrophages [See Poli etal., Proc. Natl. Acad. Sci., 87:782-784, 1990], therefore, inhibition of monokine production or activity aids in limiting HIV progression as stated above for T cells.
  • TNF has also been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus, adenovirus, and the herpes virus for similar reasons as those noted.
  • CMV cytomegalovirus
  • influenza virus influenza virus
  • adenovirus adenovirus
  • herpes virus herpes virus
  • TNF is also associated with yeast and fungal infections. Specifically Candida albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al., Infection and Immunity, 58(9):2750-54, 1990; and Jafari et al, Journal of Infectious Diseases, 164:389-95, 1991. See also Wasan et al., Antimicrobial Agents and Chemotherapy, 35,(10):2046-48, 1991; and Luke et al., Journal of Infectious Diseases, 162:211-214,1990].
  • This invention relates to the novel compounds of Formulas (I) and (II) as shown below, useful in the mediation or inhibition of the enzymatic activity (or catalytic activity) of phosphodiesterase IV (PDE IV). These compounds also have Tumor Necrosis Factor (TNF) inhibitory activity.
  • TNF Tumor Necrosis Factor
  • This invention also relates to the pharmaceutical compositions comprising a compound of Formulas (I) or (II) and a pharmaceutically acceptable carrier or diluent
  • the invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of PDE IV in mammals, including humans, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula (I) or (II) as shown below.
  • the invention further provides a method for the treatment of allergic and inflammatory disease which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I) or (II).
  • the invention also provides a method for the treatment of asthma which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I) or (II).
  • This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment, an effective TNF inhibiting amount of a compound of Formula (I) or (II). This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto.
  • This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HIV), which comprises administering to such human an effective TNF inhibiting amount of a compound of Formula (I) or (II).
  • HAV human immunodeficiency virus
  • Compounds of Formula (I) or (II) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • Rl is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, -(CR4R5) n O(CR4R5)mR6, or -(CR4Rs)rR6 wherein the alkyl moieties may be optionally substituted with one or more halogens; m is 0 to 2; n is 1 to 4; ris 1 to 6; R4 and R5 are independently selected hydrogen or C_-2 alkyl;
  • Ro " is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-,3 alkyl, halo substituted aryloxyC ⁇ _3 alkyl, indanyl, indenyl, C7-H polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4.6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclic moieties may be optionally substituted by 1 to 3 methyl groups or one ethyl group; provided that: a) when R ⁇ is hydroxyl, then m is 2; or b) when R is hydroxyl, then r is 2 to 6; or c) when R
  • X2 is O or NR8;
  • X3 is hydrogen or X
  • R2 is independently selected from -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4;
  • R3 is hydrogen, halogen, C1-4 alkyl, halo-substituted C1-4 alkyl,
  • R7 is -(CR4R5)qRi2 or C ⁇ . ⁇ alkyl wherein the R12 or Cj.g alkyl group is optionally substituted one or more times by C 1-2 alkyl optionally substituted by one to three fluorines, -F, -Br, -CI, -NO2, -Si(R4)3. -NRioRll.
  • -C(O)R8 -CO2R8, -OR ⁇ , -CN, -C(O)NRioRll, -OC(O)NRi0Rll, -OC(O)R8, -NR ⁇ C(O)NRi ⁇ Rll, -NRi0C(O)Rn, -NR ⁇ oC(O)OR9, -NRi0C(O)Rl3, -C(NRi ⁇ )NRi ⁇ Rl 1, -C(NCN)NRioRll, -C(NCN)SR9, -NRl ⁇ C(NCN)SR9 , -NR ⁇ oC(NCN)NR ⁇ oRll, -NR ⁇ oS(O)2R9, -S(O) m I R9, -NRioC(O)C(O)NRioRll, -NR ⁇ oC(O)C(O)Ri ⁇ , thiazolyl, imidazolyl, oxazolyl, pyr
  • R8 is independently selected from hydrogen or R9;
  • R8' is R ⁇ or fluorine
  • R9 is Cj_4 alkyl optionally substituted by one to three fluorines
  • RlO is OR ⁇ or Rn
  • Rl is hydrogen, or C _4 alkyl optionally substituted by one to three fluorines; or when Rio and Ri 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S;
  • Rl3 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C ⁇ _2 alkyl groups;
  • R 4 is hydrogen or R7; or when Rg and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional heteroatoms selected from O, N, or S;
  • Rl5 is C(O)Rl4, C(O)NR4Rl4, S(O)2R7, or S(O)2NR4Rl4; provided that:
  • R L is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5) R6, -(CR4R5 nO(CR4R5) m R6. or -(CR4R5)rR6 wherein the alkyl moieties may be optionally substituted with one or more halogens; m is 0 to 2; n is 1 to 4; ris 1 to 6;
  • R4 and R5 are independendy selected hydrogen or Ci-2 alkyl;
  • Ro " is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-I l polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclic moieties is unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group; provided that: a) when R6 is hydroxyl, then m is 2; or
  • Y is O or S(O) m '; m' is 0, 1, or 2; X2 is O or NR8;
  • X3 is hydrogen or X
  • R2 is independently selected from -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4; R3 is hydrogen, halogen, C1-4 alkyl, CH2NHC(O)C(O)NH2, halo-substituted
  • C1-4 alkyl, -CH CRg'Rg', cyclopropyl optionally substituted by Rg', CN, ORg, CH 2 ORg, NRgRio, CH2NRgRlO, C(Z')H, C(O)ORg, C(O)NRgR ⁇ o, or C ⁇ CRg';
  • Z' is O, NRQ, NORg, NNRgRg, NCN, C(-CN)2, CRgCN, CR8NO2, CR8C(O)OR9, CR8C(O)NR8Rg, C(-CN)NO2, C(-CN)C(O)OR9, or C(-CN)C(O)NRgRg;
  • Z" is C(Y')Ri4, C(O)ORi4, C(Y')NR ⁇ oRl4, C(NR ⁇ o)NR ⁇ oRl4, CN,
  • Rl 1, Rl3, Rl4, and R15 have the same definitions given in regards to Formula (I),where applicable; provided that: f) when R12 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N- piperazinyl, N-piperidinyl, or N-mo holinyl, then q is not 1; or g) when Z" is C(O)ORi4 where R14 is lower alkyl and R3 is CN, then R1X2 is not C1-C3 alkoxy and X is not halogen, methoxy, ethoxy, methylthio, or ethylthio; or the pharmaceutically acceptable salts thereof.
  • This invention also relates to a method of mediating or inhibiting the enzymatic activity (or catalytic activity) of PDE IV in a mammal in need thereof and to inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I) or (II).
  • Phosphodiesterase IN inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
  • PDE IV inhibitors are useful in the treatment of diabetes insipidus and central nervous system disorders such as depression and multi-infaict dementia.
  • viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, direcdy or indirectly, by the TNF inhibitors of Formula (I) or (II).
  • viruses include, but are not limited to HIV-1, HIV-2 andHTV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, Herpes zoster and Herpes simplex.
  • This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HIV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I) or (II).
  • HAV human immunodeficiency virus
  • TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections.
  • viruses include, but are not limited to feline immunodeficiency virus (FIV) or other retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other Ientiviruses.
  • the compounds of this invention are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • a preferred disease state for treatment is fungal meningitis.
  • the compounds of Formula (I) or (II) may be administered in conjunction with other drugs of choice for systemic yeast and fungal infections.
  • Drugs of choice for fungal infections include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the Amphotericins, in particular Amphotericin B and liposomal Amphotericin B.
  • polymixins such as Polymycin B
  • imidazoles such as clotrimazole, econazole, miconazole, and ketoconazole
  • triazoles such as fluconazole, and itranazole
  • Amphotericins in particular Amphotericin B and liposomal Amphotericin B.
  • the compounds of Formula (I) or (U) may also be used for inhibiting and/or reducing the toxicity of an anti-fungal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of Formula (I) or (II) to a mammal in need of such treatment.
  • a compound of Formula (I) or (II) is administered for inhibiting or reducing the toxicity of the Amphotericin class of compounds, in particular Amphotericin B.
  • Preferred compounds are as follows: When Rl for the compounds of Formula (I) or (II) is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a Ci-4 alkyl substituted by 1 or more fluorines.
  • the preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, -CHF2, -CF2CHF2.
  • Rl substitutents for the compounds of Formula (I) are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl, C7-H polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Ci-2 alkyl optionally substituted by 1 or more fluorines, -(CH2)l-3C(O)O(CH2)0-2CH3, -(CH 2 )1-3O(CH2)0-2CH3, and -(CH2)2-4OH.
  • the R4 and R5 terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as CR4R5)n or (CR4R5)m; each repeating methylene unit is independent of the other, e.g., (CR4R5)n wherein n is 2 can be -CH2CH(-CH3)-, for instance.
  • the individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can optionally be substituted by fluorine independent of each other to yield, for instance, the preferred Ri substitutions, as noted above.
  • Ri is a C7-11 polycycloalkyl
  • examples are bicyclo[2.2.
  • Preferred Z terms are O, NCN, NR7, NOR14, NOR15, NNR4R14, NNR4R15, dimethyl ketal or dimethylthio ketal. More preferred are O or NOH.
  • Preferred X groups for Formula (I) are those wherein X is YR2 and Y is oxygen.
  • the preferred X2 group for Formula (I) is that wherein X2 is oxygen.
  • the preferred X3 group for Formula (I) is that wherein X3 is hydrogen.
  • Preferred R2 groups, where applicable, is a Cl-2 alkyl optionally substituted by 1 or more halogens.
  • the halogen atoms are preferably fluorine and chlorine, more preferably fluorine.
  • More preferred R2 groups are those wherein R2 is methyl, or the fiuoro-substituted alkyls, specifically a Cl-2 alkyl, such as a -CF3, -CHF2, or -CH2CHF2 moiety.
  • R3 moieties are C(O)NH2.
  • Z' is preferably O or NORg.
  • R7 moieties include optionally substituted -(CH2)l-2(cyclopropyl), -(CH2)0-2(cyclobutyl), -(CH2)0-2(cyclopentyl), -(CH2)0-2(cycIohexyl), -(CH2)0-2(2-, 3- or 4-pyridyl), (CH2)l'-2(2-imidazolyl), (CH2)2(4-morpholinyl), (CH2)2(4-piperazinyl), (CH2)l-2(2-thienyl), (CH2)l-2(4-thiazolyl), and (CH2)0-2phenyl;
  • Preferred rings when Rio and Rl 1 in the moiety -NRioRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1- imidazolyl, 2-(Rg)-l-imidazolyl, l-pyrazolyl, 3-(R8)- l-pyrazolyl, 1-triazolyl, 2-triazolyl, 5-(Rg)-l-triazo-yl, 5-(Rg)-2-triazolyl, 5-(Rg)-l-tetrazolyl, 5-(Rg)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazIoyl, morpholinyl, piperazdnyl, 4-(Rg)-l-piperazinyl, orpyrrolyl ring.
  • the respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I).
  • Illustrations of such carbon substitutions includes, but is not limited to, 2-(R7)-l-imidazolyl, 4-(R7)-l-imidazolyl, 5-(R7)-l-imidazolyl, 3-(R7)-l-pyrazolyl, 4-(R7)-l-pyrazolyl, 5-(R7)-l-pyrazolyl, 4-(R7)-2-triazolyl, 5-(R7)-2-triazolyl, 4-(R7)-l-triazoIyl, 5-(R7)-l-triazolyl, 5-(R7)-l-tetrazolyl, and 5-(R7)-2-tetrazolyl.
  • R7 Applicable nitrogen substitution by R7 includes, but is not limited to, l-(R7)-2-tetrazolyl, 2-(R7)-l-tetrazolyl, 4-(R7)-l-piperazinyl. Where applicable, the ring may be substituted one or more times by R7.
  • Preferred groups for NRgRi4 which contain a heterocyclic ring are 5-(Ri4)-l- tetrazolyl, 2-(Ri4)-l-imidazolyl, 5-(Ri4)-2-tetrazolyl, 4-(Ri4)-l-p ⁇ perazinyl, or 4-(Ri5)-l-piperazinyl.
  • Preferred rings for R 3 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[l,2,3]), (3- or 5-triazolyl[l,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[l,3,4]), (2-thiadiazolyl[l,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl).
  • the heterocyclic ring itself may be optionally substituted by Rg either on an available nitrogen or carbon atom, such as l-(Rg)-2-imidazolyl, l-(Rg)-4-imidazolyl, l-(Rg)-5-imidazolyl, l-(Rg)-3-pyrazolyl, l-(Rg)-4-pyrazolyl, l-(R8)-5-pyrazolyl, l-(R8)-4-triazolyl, or l-(Rg)-5-triazolyl.
  • the ring may be substituted one or more times by Rg.
  • R is -CH2-cyclopropyl, -CH2-C5-6 cycloalkyl, -C4-6 cycloalkyl, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl or -Cl-2 alkyl optionally substituted by 1 or more fluorines, and -(CH2)2-4 OH;
  • R2 is methyl or fluoro-substituted alkyl, R3 is CN or C ⁇ CRg; and
  • X is YR2.
  • Ri is -CH2-cyclopropyl, cyclopentyl, methyl or CF2H
  • R3 is CN or C ⁇ CH
  • X is YR2
  • Y is oxygen
  • X2 is oxygen
  • X3 is hydrogen
  • R2 is CF2H or methyl.
  • a preferred subgenus of Formula (I) are the compounds of Formula (Ia)
  • Rj is CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl, C7-11 polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Cl-2 alkyl optionally substituted by 1 or more fluorines, -(CH2)l-3C(O)O(CH2) ⁇ -2CH3, -(CH2)1-3O(CH2)0-2CH 3 , and -(CH2)2-4OH;
  • X is YR2, halogen, nitro, NR4R5, or formyl amine
  • Y is O or S(O) m '; m' is 0, 1, or 2;
  • R2 is -CH3 or -CH2CH3 optionally substituted by 1 or more halogens;
  • R3 is hydrogen, Ci-4 alkyl, halo-substituted C1-4 alkyl CH2C(O)C(O)N,
  • R7 is -(CR4R5)qRi2 or C ⁇ _6 alkyl wherein the R12 or C ⁇ _6 alkyl group is optionally substituted one or more times by Cl-2 alkyl optionally substituted by one to three fluorines, -F, -Br, -CI, -NO2, -Si(R_.)3, -NR 10 R ⁇ , -C(O)R8, -CO2Rg, -ORg, -CN, -C(O)NRl ⁇ Rn, -OC(O)NRioRll, -OC(O)R8, -NRi ⁇ C(O)NRl ⁇ Rl l, -NR ⁇ oC(O
  • Rl2 is C3-7 cycloalkyl, (2-, 3- or 4-pyridyl), (1- or 2-imidazolyl), piperazinyl, morpholinyl, (2- or 3-thienyl), (4- or 5-thiazolyl), or phenyl;
  • Rg is independently selected from hydrogen or R9;
  • R9 is C ⁇ _4 alkyl optionally substituted by one to three fluorines;
  • Rl 1 is hydrogen or C1-4 alkyl optionally substituted by one to three fluorines; or when R ⁇ o and R ⁇ are as NR10R11 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S;
  • Rl3 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazol ⁇ dinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C ⁇ _2 alkyl groups;
  • R ⁇ is hydrogen or R7; or when Rg and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring optionally contaimng one or more additional heteroatoms selected from O, N, or S;
  • Rl5 is C(O)Rl4, C(O)NR4Rl4, S(O)2R7. or S(O)2NR4Rl4; provided that: a) when Z is O, X is YR2, Y is oxygen, R2 is CH3, and Ri is CH3, then R3 is other than CN; b) when R12 is N-imidazolyl, N-triazolyl, N-pyrrolyl, N-piperazinyl, orN- morpholinyl, then q is not 1; or the pharmaceutically acceptable salts thereof.
  • Preferred Z" groups are for compounds of the Formula (II) are C(O)Ri4, C(O)ORi4, C(O)NR ⁇ oRl4, C(NR ⁇ o)NR ⁇ oRl4, CN, C(NORg)R ⁇ , C(O)NRgNRgC(O)Rg, C(O)NRgNR ⁇ oRl4, C(NORi4)Rg, C(NRg)NR ⁇ oRl4,
  • C ⁇ _ 3 alkyl C1.4 alkyl
  • Ci.g alkyl or “alkyl” groups as used herein is meant to include both straight or branched chain radicals of 1 to 10, unless die chain length is limited diereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl, tert-butyl, and die like.
  • Alkenyl means both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1-propenyl, 2- propenyl, 2-propynyl, or 3-methyl-2-propenyl.
  • cycloalkyl or "cycloalkyl alkyl” means groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl.
  • Aryl or “aralkyl”, unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl, ornaphthyl.
  • the aryl is monocyclic, i.e, phenyl.
  • the alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms.
  • Heteroaryl means an aromatic ring system contaimng one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl.
  • Halo means all halogens, i.e., chloro, fluoro, bromo, or iodo.
  • “Inhibiting the production of IL-1” or “inhibiting the production of TNF” means: a) a decrease of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels by inhibition of the in vivo release of IL-1 by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcriptional level, of excessive in vivo J-L-l or TNF levels, respectively, in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of IL-1 or TNF levels as a postranslational event.
  • TNF mediated disease or disease states means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to EL-1 or IL-6.
  • TNF- ⁇ also known as lymphotoxin
  • TNF- ⁇ also known as cachectin
  • TNF- ⁇ also known as cachectin
  • both TNF- ⁇ and TNF- ⁇ are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF” unless specifically delineated otherwise.
  • TNF- ⁇ is inhibited.
  • Cytokine means any secreted polypeptide that affects the functions of cells, and is a molecule which modulates interactions between cells in immune, inflammatory, or hematopoietic responses.
  • a cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce diem.
  • the cytokine inhibited by the present invention for use in the treatment of a HTV- infected human must be a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HTV gene expression and/or replication, and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration.
  • his cytokine is TNF- ⁇ .
  • All of the compounds of Formula (I) and (II) are useful in the method of inhibiting the production of TNF, preferably by macrophages, monocytes or macrophages and monocytes, in a mammal, including humans, in need thereof. All of the compounds of Formula (I) and (H) are useful in the method of inhibiting or mediating the enzymatic or catalytic activity of PDE IV and in treatment of disease states mediated thereby.
  • METHODS OF PREPARATION Preparing compounds of Formula (I) can be carried out by one of skill in the art according to the procedures outlined in die Examples, infra.
  • any remaining compounds of Formula (I) not described therein may be prepared by die analogous processes disclosed herein which comprise: a) for compounds wherein X and Xi are other than Br, I, NO2, amine, formyl amine, or S(O)m' when m' is 1 or 2, reacting a compound of Formula (2)
  • Ri represents Ri as defined in relation to Formula (I) or a group convertable to Ri
  • X represents X as defined in relation to Formula (I) or a group convertable to X
  • X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 and
  • Xi is H, widi a lithium halide and a silyl halide in an appropriate solvent followed by reduction with an appropriate reductant, such as a siloxane, to provide a compound of Formula (3) wherein X4 is a halide.
  • reduction of a compound of Formula (2) wherein X is H widi a suitable reductant, such as sodium borohydride provides a compound of Formula (3) wherein X4 is OH.
  • halide displacement by cyanide provides a compound of Formula (3) wherein X4 is CN.
  • a compound of Formula (5) [a subset of me compounds of Formula (II)] may be obtained direcdy from a compound of Formula (3) wherein X4 and Ri6 are as described above by reaction with an excess of an acrylate, such as methyl, ethyl, phenyl, benzyl, or t- butyl acrylate, with excess base, such as a metal hydride, in a suitable non-reacting solvent, such as tetrahydrofuran or 1,2-dime oxyed ⁇ ane, at an elevated temperature.
  • an acrylate such as methyl, ethyl, phenyl, benzyl, or t- butyl acrylate
  • excess base such as a metal hydride
  • a compound of Formula (2) wherein Xi is H may be homologated to a compound of Formula (3) wherein X4 is COOR17 by any number of processes known in the art, such as reaction with methyl methylsulfinyl-methyl sulfide and a base, such as sodium hydroxide, followed by treatment with, for example, alcoholic (R17OH) acid.
  • Reaction of a compound of Formula (4) wherein X4 is COOR17 and Ri6 and R17 are independently an alkyl, phenyl, or benzyl group with a base, such as excess metal hydride, in a suitable non-reacting solvent, such as tetrahydrofuran or 1,2-dimemoxyethane, at an elevated temperature then provides a compound of Formula (5) wherein Xi is COOR17 and Ri6 and R17 are independendy an alkyl, phenyl or benzyl group.
  • the keto carbonyl of such a compound of Formula (I) may require protection as, e.g., a ketal, prior to ester or amide formation, with liberation of the protected ketone under appropriate mild acidic conditions as the final step.
  • the simple amide derivative, that in which R3 is CONH2 and Z is O, may be treated, after appropriate protection of the ketone, with a dehydrating agent to provide, after ketone deprotection, the compound of Formula (I) in which R3 is CN and Z is O.
  • Compounds of Formula (I) wherein R3 is CHO and Z is O may be prepared from the compound of Formula Q in which R3 is CN and Z is O after appropriate protection of die ketone as, e.g., a ketal, followed by reduction of the CN moiety with, e.g., di- isobutylaluminum hydride, followed by appropriate workup and ketone deprotection.
  • die ketone as, e.g., a ketal
  • reduction of the CN moiety e.g., di- isobutylaluminum hydride, followed by appropriate workup and ketone deprotection.
  • DAST diediyl-aminosulfur trifluoride
  • Compounds of Formula (I) wherein R3 is CF3 and Z is O may be prepared from the compound of Formula (3) wherein X2 is CF3 using the procedures described above for preparation of the compounds of Formula (I) wherein R3 is CN or COOR16 and Z is O; the compound of Formula (3) wherein X2 is CF3 may be prepared in turn from the compound of Formula (2) wherein Xi is H either electrochemically by the method of Shono et al., J. Org. Chem., 56:2-4, 1991, or by treating a compound of Formula (6)
  • X5 is, e.g., bromine, with a metalling agent, such as an alkyl lithium, in an inert solvent, such as tetrahydrofuran or 1,2-dimethoxyeti ⁇ ane, at -78° C followed by the trifluoroacetic acid or difluoro acetic acid by die metiiod of Nad et ⁇ /. zvest, 71, 1959: Chem. Abstr., 53, No. 14977 and 53, No. 17933 ,1959, to provide a compound of
  • certain compounds of Formula (I) wherein Z is O and R3 is COOR8 may be prepared by reducing die double bond of die cyclohexenone synthetic intermediates produced by die method of Parkinson and Pinhey, J. Chem. Soc. Peri ⁇ n Trans.1, 1053-7, 1991, incorporated herein by reference in its entirety. Similar double bond reduction of the corresponding synthetic intermediates wherein R3 is CN derived by analogous procedures using 4-cyano-3-cyclohexen-l-one and/or 4-cyano-2-cyclohexen-l- one may provide certain compounds of Formula (I) wherein Z is O and R3 is CN.
  • Compounds of Formula (II) wherein R14 in C(O)ORl4 of the Z" group is other than an alkyl, phenyl, or benzyl group are obtained from compounds of Formula (5) or from otiier compounds of Formula (H) by standard transesterification procedures.
  • other compounds of the Formula (II) e.g., Z" amides, aldehydes, ketones, hydrazides, etc., may be prepared from other compounds of the Formula (II) by, e.g., standard functional group manipulation of the Z" group, either proceeding or following functional group manipulation of the R3 group.
  • some compounds of Formula (II) may be prepared by reaction of an appropriate compound of Formula (I) with an appropriate base in the appropriate proportions under die appropriate conditions followed by reaction with a haloformate, such as metiiyl or ediyl chloroformate, or by treatment of an appropriate compound of Formula (I) with methyl methoxy magnesium carbonate; such compounds of the Formula (II) may then be converted to odier compounds of die Formula (II) by the techniques described above and below.
  • a haloformate such as metiiyl or ediyl chloroformate
  • some compounds of die Formula (II) may be prepared by reacting a compound of die Formula (3) wherein Rl represents Ri as defined in relation to Formula (I) or a group convertable to Rl and X, X2 and X3 represent X, X2 and X3 as defined in relation to Formula (I) or a group convertable to X, X2 or X3 and R3 represents R3 as defined in relation to Formula (I) or a group convertable to R3, and X4 is CN with an excess of acrylonitrile in the presence of a base, such as excess metal hydride, or catalytic or excess quaternary amine base, such as benzyltrimetiiylammonium hydroxide, in a suitable non-reacting solvent, such as tetrahydrofuran or 1,2-dimethoxyethane when a metal hydride base is used or these sovents or acetonitrile when a quaternary amine base is used, to provide a base
  • X4 is CN; reaction of a compound of the Formula (7) with a base, such as excess metal hydride, in a suitable non-reacting solvent, such as tetrahydrofuran or 1,2- dimethoxyethane, at an elevated temperature then provides a compound of the Formula (8) wherein X4 is CN and X5 and X ⁇ are both H; alternatively, a compound of die Formula (8) may be obtained direcdy from a compound of Formula (7) wherein X4 is as described above by reaction with an excess of optionally R2-substituted acrylonitrile, with excess base, such as a metal hydride, in a suitable non-reacting solvent, such as tetrahydrofuran or 1,2-dimethoxyethane, at an elevated temperature.
  • a base such as excess metal hydride
  • X5 is H
  • compounds of the Formula (9) are prepared by heating compounds of the Formula (9) in a solution of hydrazoic acid generated in situ by, e.g., admixture of an alkalai metal azide, such as sodium azide, widi an ammonium halide, such as triethylamine hydrochloride, in a polar non-protic solvent such as N-methylpyrrolidinone.
  • an alkalai metal azide such as sodium azide
  • ammonium halide such as triethylamine hydrochloride
  • a 2-(R2)- or 3-(R2)-acrylate provides, respectively and sequentially, the 2,6-(R2)2- or 3,5-(R2)2-pimelates of Formula (4), the 2,6-(R2)2- or 3,5- (R2)2-2-(COORi6)-cyclohexanones of Formula (5) and then the 2,6-(R2)2- or 3,5-(R2)2- cyclohexanones of Formula (T).
  • a 2,3-(R2)2- or 3,3-(R2)2-acrylate provides, respectively and sequentially, the 2,3,5,6-(R2)4- or 3,3,5,5-(R2)4-pimelates of Formula (4), the 2,3,5,6-(R2)4- or 3,3,5,5-(R2)4-2-(COORi6)-cyclohexanones of Formula (5) and then the 2,3,5,6-(R2)4- or 3,3,5,5-(R2)4-cyclohexanones of Formula (I).
  • reaction of an appropriate compound of Formula (I) with an appropriate base in the appropriate proportions under the appropriate conditions followed by reaction with an alkylating agent, R2L, wherein L is a leaving group provides die 2-(R2)-, 2,2-(R2)2-. 2,6- (R2)2- » or 2,2,6,6-(R2)4-cyclohexanones of Formula (I); similar reaction of an appropriately alkylated compound of Formula (I), e.g., 3,5-(R2)2- or 2,6-(R2)2- cyclohexanone, provides, e.g., 2,3,5-(R2)3- or 2,2,6-(R2)3-cyclohexanone of Formula (I), respectively.
  • R2L alkylating agent
  • Such compounds of Formula (I) may then be converted to other compounds of Formula (I) using the general techniques and, when necessary, appropriate protection and deprotection of chemically sensitive functionalities, described above; likewise, such compounds of Formula (II) may be converted to odier compounds of Formula (II) using the general techniques and, when necessary, appropriate protection and deprotection of chemically sensitive functionalities, described above.
  • Methyl acrylate (27 mL, 303 mmol) was added carefully, the reaction mixture was maintained at reflux for 5h and then cooled. The mixture was diluted widi edier, was washed once with IN hydrochloric acid and once widi brine, was dried (magnesium sulfate) and die solvent was removed in vacua. The solid residue was triturated wid 5% ethanol/hexane to provide a white solid (9 g, 74%): m.p. 81- 82°C; and additional 1.1 g (9%) was also obtained from the filtrate. Analvsis Calc.
  • EXAMPLE 2 4-(3.4-Bisdifluorometfioxyphenyl -2-carbomethoxy-4-cvanocvclohexan-l-one 2a.
  • 3.4-Bisdifluoromethoxybenzaldehyde A vigorously stirred mixture of 3,4- dihydroxybenzaldehyde (40 g, 290 mmol) and powdered potassium carbonate (120 g, 870 mol) in dimediylformamide (500 mL) was heated under an atmosphere of chlorodifluoromediane at 80°C for 7h and then was stirred at room temperature overnight.
  • Trimethylsilylchloride (1.86 mL, 14.7 mmol) was slowly added and die reaction mixture was allowed to warm to room temperature and was stirred for 15 min. The reaction mixture was again cooled to 0°C, 1,1,3,3-tetramethyldisiloxane (2.6 mL, 14.7 mmol) was added and die resulting mixture was allowed to warm to room temperature. After stirring for 3h, the mixture was separated into two layers. The lower layer was removed, diluted widi mediylene chloride and filtered. The filtrate was concentrated under reduced pressure, dissolved in methylene chloride and refiltered.
  • EXAMPLE 5 2-Carbomethoxy-4-cvano-4-r3-cyclopentyloxy-4-difluoromethoxyphenyl)cyclohexan-l-one 5a.
  • 4-Difluoromethoxy-3-hydroxybenzaldehyde A vigorously stirred mixture of 3,4- dihydroxybenzaldehyde (50 g, 362 mmol) and powdered potassium carbonate (50 g, 362 mol) in dimethylformamide (250 mL) was heated at 100°C under an atmosphere of chlorodifluoromethane using a -78°C condenser for 5.5h. An additional quantity of potassium carbonate (10 g) was added and die reaction was continued for anotiier 0.5h.
  • the resulting mixture was refluxed for 20 min, additional 1,2- dimedioxyediane (50 mL) was added and the mixture was refluxed for another 70 min.
  • the mixture was cooled to 0°C, was acidified with dilute hydrochloric acid and was concentrated.
  • the mixture was partitioned between ether and dilute hydrochloric acid, d e organic layer was dried (magnesium sulfate) and the solvent was removed in vacuo.
  • the product was purified by flash chromatography, eluting with 85:15 hexanes/ethyl acetate, to provide a white solid (0.76 g, 37%): m.p. 109-110.5 O C.
  • EXAMPLE 12 4-Cvano-4-(3-cvclopropylmethoxy-4-difluoromemoxyphenyl)cvclohexan-l-one
  • 2-carbomethoxy-4-cyano-4-(3-cyclopentyloxy-4- difluoromethoxyphenyl)cyclohexan-l-one 0.5 g, 1.27 mmole
  • dimetiiyl sulfoxide 10 mL
  • water 1 mL
  • sodium chloride 0.5 g
  • EXAMPLE 14 4-f 3-Cyclopentyloxy-4-methoxyphenyl)-4-form ylcvclohexa ⁇ - 1 -one 14a.
  • a mixture of 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l-one (0.5 g, 1.6 mmol), trimethyl orthoformate (0.21 mL, 1.9 mmol) and a catalytic amount of p- toluenesulfonic acid in methanoi (20 mL) was heated gendy under an argon atmosphere for 2h.
  • EXAMPLE 16 4-(3-Cyclopentyloxy-4-methoxyphenyl')-4-Cfluoromed ⁇ yl ' )cyclohexan-l-one 16a. 4-(3-Cyclopentyloxy-4-methoxyphenvI)-4-(fluoromethyl)cvclohexan-l-one dimethyl ketal A solution of 4-(3-cyclopentyloxy-4-methoxyphenyl)-4- (hydroxymed ⁇ yl)cyclohexan-l-one dimetiiyl ketal (0.37 g, 1.02 mmol) in methylene chloride (5 mL) was added dropwise to a solution of diediylaminosulfur trifluoride (0.14 mL, 1.02 mmol) at -78°C under an argon atmosphere.
  • EXAMPLE 17 4-Aminocarbonyl-4-(3-cvclopentyloxy-4-methoxyphenyl)cvclohexan- 1 -one 17a. 4-Aminocarbonyl-4-( ' 3-cyclopentyloxy-4-me_ ⁇ oxyphenyl)cvclohexan-l-one dimethyl ketal A solution of 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l- one dimethyl ketal (0.34 g, 0.95 mmol) and powdered potassium carbonate (0.7 g, 5.1 mmol) in methanol (20 mL) and water (4 mL) at 0°C was treated with hydrogen peroxide (30% solution, 2.55 mL).
  • EXAMPLE 19 4-(3.4-Bisdifluoromethoxyphenyl)-4-ethynylcvclohexan-l-one 19a. 4-G.4-Bisdifluoromethoxyphenyl)-4-cvanocvclohexan-l-one dimethyl ketal A mixture of 4-cyano-4-(3,4-bisdifluoromethoxyphenyl)cyclohexan-l-one (1.34 g, 4.05 mmol), trimediyl orthoformate (0.53 mL, 4.85 mmol) and a catalytic amount of p- toluenesulfonic acid in medianol (40 mL) was heated gendy under an argon atmosphere for 2h.
  • EXAMPLE 20 4-(3.4-Bisdifluoromed ⁇ oxyphenyl)-4-(oxamidomethyl)cyclohexan-l-one 20a. 4-Aminomethyl-4-(3.4-bisdifluoromethoxyphenyl)cyclohexan- 1 -one dimetiiyl ketal A solution of 4-(3,4-bisdifluoromed ⁇ oxyphenyl)-4-cyanocyclohexan- 1 -one dimetiiyl ketal (0.5 g, 1.33 mmol) in tetrahydrofuran (3 mL) at room temperature under an argon atmosphere was added to a suspension of lithium aluminum hydride (0.1 g, 2.66 mmol) in tetrahydrofuran (4.5 mL).
  • 2-Aminocarbonyl-4-cvano-4-(3-cyclopropylmethoxy-4-methoxyphenv ⁇ cvclohexan-l-one 26a 2-Carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)-l- (methoxymethyloxy)cyclohex- 1 -ene
  • 2-carbomethoxy-4-cyano-4-(3- cyclopropylmethoxy-4-methoxyphenyl)-l- (methoxymethyloxy)cyclohex- 1 -ene A solution of 2-carbomethoxy-4-cyano-4-(3- cyclopropylmethoxy-4-methoxyphenyl)cyclohexan-l-one (1.0 g, 2.8 mmol) and sodium hydride (80% dispersion in mineral oil, 0.09 g, 3.1 mmol) in dry hexamethylphosphoric triamide (8 mL) was stirred under an
  • EXAMPLE 28 4- ( 3-Cvclopropylmethoxy-4-difluoromethoxyphenyl)-2.4-dicvanocvclohexan-l-one To a stirred solution of l-amino-4-(3-cyclopropylmethoxy-4- difluoromed ⁇ oxyphenyl])-2,4-dicyanocyclohex-l-ene (0.25 g, 0.696 mmol) in ethanol (2 mL) was added 6N hydrochloric acid (0.6 mL) and the mixture was stirred for 1.5h at ambient temperature.
  • RESULTS OF TREATMENT Li order to use a compound of Formula (I) or (II) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance widi standard pharmaceutical practice as a pharmaceutical composition.
  • the compounds of Formula (I) or (II), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for die prophylatic or therapeutic treatment of any disease state in a human or odier mammal which is mediated by inhibition of PDE IV, such as but not limited to asthma, allergic, or inflammatory diseases.
  • the compounds of Formula CD or (II) are administered in an amount sufficient to treat such a disease in a human or odier mammal.
  • the amount of a compound of Formula (I) or (II) required for therapeutic effect on topical administration will, of course, vary with the compound chosen, die nature and severity of the condition and die animal undergoing treatment, and is ultimately at the discretion of the physician.
  • the daily dosage regimen for oral administration is suitably about .001 mg/kg to lOOmg/kg, preferably 0.01 mg Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity.
  • EXAMPLE A Inhibitory effect of compounds of Formula (I) or (II) on in vitro TNF production by human monocytes
  • the inhibitory effect of compounds of Formula (I) or (II) on in vitro TNF production by human monocytes may be determined by the protocol as described in Badger et al., EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990.
  • EXAMPLE B Two models of endotoxic shock have been utilized to determine in vivo T ⁇ F activity for the compounds of Formula (I) or (II).
  • the protocol used in tiiese models is described in Badger et al., EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990.
  • Example 1 demonstrated a positive in vivo response in reducing serum levels of T ⁇ F induced by the injection of endotoxin.
  • PDE Isozymes The phosphodiesterase inhibitory activity and selectivity of die compounds of Formula CD or (H) can be determined using a battery of five distinct PDE isozymes.
  • the tissues used as sources of die different isozymes are as follows: 1) PDE lb, porcine aorta; 2) PDE Ic, guinea-pig heart; 3) PDE HI, guinea-pig heart; 4) PDE IV, human monocyte; and 5) PDE V (also called "Ia”), canine trachealis.
  • PDEs Ia, lb, Ic and in are partially purified using standard chromatographic techniques [Torphy and Cieslinski, Mol.
  • PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-Sepharose chromatography [Torphy et al., J. Biol. Chem., 267:1798-1804, 1992].
  • Phosphodiesterase activity is assayed as described in the protocol of Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990. Positive ICso's in the nanomolar to ⁇ M range for compounds of die workings examples described herein for Formula (D or (II) have been demonstrated.
  • EXAMPLE D The ability of selected PDE IV inhibitors to increase cAMP accumulation in intact tissues is assessed using U-937 cells, a human monocyte cell line that has been shown to contain a large amount of PDE IV.
  • U-937 cells a human monocyte cell line that has been shown to contain a large amount of PDE IV.
  • nondifferentiated U-937 cells approximately 10-5 cells/reaction tube
  • PDE inhibitors were incubated with various concentrations (0.01-1000 ⁇ M) of PDE inhibitors for one minute and l ⁇ M prostaglandin E2 for an additional four minutes. Five minutes after initiating the reaction, cells were lysed by die addition of 17.5% perchloric acid, die pH was neutralized by die addition of 1M potassium carbonate and cAMP content was assessed by RIA.

Abstract

L'invention décrit de nouveaux cyclohexanes représentés par les formules (I) et (II); ces derniers inhibent la production du facteur de nécrose tumorale (TNF) et sont efficaces dans le traitement de maladies provoquées ou amplifiées par la production TNF. Lesdits composés sont également efficaces dans la médiation ou l'inhibition de l'activité enzymatique ou catalytique de la phophodiestérase IV.
PCT/US1993/002325 1992-04-02 1993-03-12 Composes efficaces dans le traitement de maladies allergiques ou inflammatoires WO1993019750A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE69330459T DE69330459T2 (de) 1992-04-02 1993-03-12 Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
AT93907493T ATE203159T1 (de) 1992-04-02 1993-03-12 Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
DK93907493T DK0636025T3 (da) 1992-04-02 1993-03-12 Forbindelser, der er egnede til behandling af allergiske og inflammatoriske sygdomme
EP93907493A EP0636025B1 (fr) 1992-04-02 1993-03-12 Composes efficaces dans le traitement de maladies allergiques ou inflammatoires
CA002133337A CA2133337C (fr) 1992-04-02 1993-03-12 Composes pour le traitement des allergies et des inflammations
JP51746793A JP3192424B2 (ja) 1992-04-02 1993-03-12 アレルギーまたは炎症疾患の治療用化合物
MA23147A MA22858A1 (fr) 1992-04-02 1993-04-01 Procede pour la preparation de nouveaux composes .
SI9300168A SI9300168A (sl) 1992-04-02 1993-04-02 3,4-disubstttuirani fenilcikloheksan-1-oni za zdravljenje bolezni, ki so v zvezi s pdeiv
US08/488,556 US5811455A (en) 1992-04-02 1995-05-24 Compounds useful for treating allergic or inflammatory diseases
HK98113532A HK1012262A1 (en) 1992-04-02 1998-12-15 Compounds useful for treating allergic or inflammatory diseases
GR20010401717T GR3036853T3 (en) 1992-04-02 2001-10-09 Compounds useful for treating allergic or inflammatory diseases.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US86208392A 1992-04-02 1992-04-02
US07/862,083 1992-04-02
US96875392A 1992-10-30 1992-10-30
US07/968,753 1992-10-30
USPCT/US93/02045 1993-03-05
US9302045 1993-03-05

Publications (1)

Publication Number Publication Date
WO1993019750A1 true WO1993019750A1 (fr) 1993-10-14

Family

ID=27377343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/002325 WO1993019750A1 (fr) 1992-04-02 1993-03-12 Composes efficaces dans le traitement de maladies allergiques ou inflammatoires

Country Status (4)

Country Link
JP (1) JP3192424B2 (fr)
KR (1) KR100344712B1 (fr)
IL (1) IL105218A0 (fr)
WO (1) WO1993019750A1 (fr)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633776A1 (fr) * 1992-04-02 1995-01-18 Smithkline Beecham Corporation Composes destines a traiter les maladies allergiques et inflammatoires
EP0710109A1 (fr) * 1993-06-18 1996-05-08 Smithkline Beecham Corporation Composes
EP0727990A1 (fr) * 1993-10-01 1996-08-28 Smithkline Beecham Corporation Composes, compositions et traitement d'allergies et de l'inflammation
EP0749417A1 (fr) * 1994-03-11 1996-12-27 Smithkline Beecham Corporation Composes de cyano et leur preparations
EP0796092A1 (fr) * 1994-12-23 1997-09-24 Smithkline Beecham Corporation Dimeres de 3,3-(disubstitue)cyclohexan-one et composes apparentes
EP0799183A1 (fr) * 1994-12-23 1997-10-08 Smithkline Beecham Corporation Monomeres de 3,3-(disubstitue)cyclohexan-1-one et composes apparentes
EP0800393A1 (fr) * 1994-12-23 1997-10-15 Smithkline Beecham Corporation Monomeres de 4,4-(disubstitue)cyclohexan-1-one et composes correspondants
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5840724A (en) * 1993-06-01 1998-11-24 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or
WO1999011607A1 (fr) * 1997-08-28 1999-03-11 Lonza Ag Procede pour produire un 1-(3-cyclopentyloxy- 4-alcoxyphenyl)-4- oxocyclohexanecarbonitrile
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
US6255326B1 (en) 1991-01-28 2001-07-03 Aventis Pharma Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
EP1202955A2 (fr) * 1999-08-10 2002-05-08 SmithKline Beecham Corporation 4,4-diaryl cyclohexanes substitues en 1-4
WO2006056471A1 (fr) 2004-11-29 2006-06-01 Novartis Ag Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2
WO2007071400A1 (fr) 2005-12-22 2007-06-28 Novartis Ag Derives de pyrazine en tant que bloqueur du canal sodique epithelial
WO2007121920A2 (fr) 2006-04-21 2007-11-01 Novartis Ag Composés organiques
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
WO2008052734A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composés hétérocycliques en tant qu'agents anti-inflammatoires
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
WO2009150137A2 (fr) 2008-06-10 2009-12-17 Novartis Ag Composés organiques
EP2206499A1 (fr) 2004-11-02 2010-07-14 Novartis AG Derives de quinuclidine et leur utilisation en tant qu'antagonistes des recépteurs muscariniques m3
WO2010088335A1 (fr) 2009-01-29 2010-08-05 Novartis Ag Benzimidazoles substitués destinés au traitement d'astrocytomes
EP2253612A1 (fr) 2005-04-14 2010-11-24 Novartis AG Composés organiques
EP2270008A1 (fr) 2005-05-20 2011-01-05 Novartis AG 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones comme inhibiteurs de kinases lipidiques et/ou de la pi3 kinase
EP2279777A2 (fr) 2007-01-10 2011-02-02 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéase à activation de canal
EP2281819A1 (fr) 2004-01-21 2011-02-09 Novartis AG Dérivés du benzimidazole ou du benzoxazole
WO2011015652A1 (fr) 2009-08-07 2011-02-10 Novartis Ag Dérivés 3-hétéroarylméthyl-imidazo[1,2-b]pyridazin-6-yliques comme modulateurs de la tyrosine kinase c-met
WO2011018454A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composés hydrazone hétérocycliques et leurs utilisations pour traiter le cancer et l'inflammation
EP2286813A2 (fr) 2006-01-31 2011-02-23 Novartis AG Utilisation de dérivés de naphthyridine comme medicaments
WO2011022439A1 (fr) 2009-08-17 2011-02-24 Intellikine, Inc. Composés hétérocycliques et leurs utilisations
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
EP2292619A1 (fr) 2004-10-22 2011-03-09 Novartis AG Derivés de purin et leurs utilisation comme agonists d'adenosin-A2A-récepteur
WO2011050325A1 (fr) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques
EP2332933A1 (fr) 2007-05-07 2011-06-15 Novartis AG Inhibiteurs du canal sodique épithélial
WO2011113894A1 (fr) 2010-03-19 2011-09-22 Novartis Ag Dérivés de pyridine et de pyrazine pour le traitement de la mucoviscidose
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012034091A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions à titre d'inhibiteurs de trk
WO2012035158A1 (fr) 2010-09-17 2012-03-22 Novartis Ag Dérivés de la pyrazine en tant que bloqueurs de l'enac
EP2444120A1 (fr) 2007-12-10 2012-04-25 Novartis AG Analogues d'Amiloride spirocyclique en tant que blocker d'ENaC
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
EP2532677A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
WO2013030802A1 (fr) 2011-09-01 2013-03-07 Novartis Ag Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038362A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
WO2013038390A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Hétérocyclyle carboxamides n-substitués
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013140319A1 (fr) 2012-03-19 2013-09-26 Novartis Ag Forme cristalline d'un sel de succinate
WO2013149581A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2014132220A1 (fr) 2013-03-01 2014-09-04 Novartis Ag Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2015162461A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162459A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162456A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
WO2016011956A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
WO2016016822A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polythérapie
EP3603634A1 (fr) 2004-05-18 2020-02-05 Novartis AG Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique
WO2020250116A1 (fr) 2019-06-10 2020-12-17 Novartis Ag Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie
WO2021038426A1 (fr) 2019-08-28 2021-03-04 Novartis Ag Dérivés de 1,3-phényl hétéroaryle substitués et leur utilisation dans le traitement d'une maladie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795757A (en) * 1984-09-04 1989-01-03 Rorer Pharmaceutical Corporation Bisarylamines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA90A (en) * 1869-10-01 C.H. Waterous A set gauge for sawing machines
CA70A (en) * 1869-09-18 H. Baines Improvements in reworking old railway iron or rails or bars

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795757A (en) * 1984-09-04 1989-01-03 Rorer Pharmaceutical Corporation Bisarylamines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, 12 March 1979, AGEKYAN et al., August, No. 90:86895p, see formula I. *
CHEMICAL ABSTRACTS, 23 November 1970, TREIBER et al., Abstract No. 109530f, see formula II. *
See also references of EP0636025A4 *

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255326B1 (en) 1991-01-28 2001-07-03 Aventis Pharma Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5643946A (en) * 1992-04-02 1997-07-01 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5614540A (en) * 1992-04-02 1997-03-25 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0633776A4 (fr) * 1992-04-02 1995-01-25
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5602157A (en) * 1992-04-02 1997-02-11 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0633776A1 (fr) * 1992-04-02 1995-01-18 Smithkline Beecham Corporation Composes destines a traiter les maladies allergiques et inflammatoires
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5840724A (en) * 1993-06-01 1998-11-24 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or
EP1466598A3 (fr) * 1993-06-18 2007-06-27 Smithkline Beecham Corporation Inhibiteurs de pde 4
EP0710109A4 (fr) * 1993-06-18 1999-01-20 Smithkline Beecham Corp Composes
EP0710109A1 (fr) * 1993-06-18 1996-05-08 Smithkline Beecham Corporation Composes
EP1466598A2 (fr) * 1993-06-18 2004-10-13 Smithkline Beecham Corporation Inhibiteurs de pde 4
US6143782A (en) * 1993-06-18 2000-11-07 Smithkline Beecham Corporation Anti-inflammatory and anti-asthma treatment with reduced side effects
EP0727990A4 (fr) * 1993-10-01 1999-03-10 Smithkline Beecham Corp Composes, compositions et traitement d'allergies et de l'inflammation
EP0727990A1 (fr) * 1993-10-01 1996-08-28 Smithkline Beecham Corporation Composes, compositions et traitement d'allergies et de l'inflammation
EP0749417A1 (fr) * 1994-03-11 1996-12-27 Smithkline Beecham Corporation Composes de cyano et leur preparations
EP1279662A1 (fr) * 1994-03-11 2003-01-29 SmithKline Beecham Corporation Procédé de préparation d'acides phénylcyclohexan-1-yl carboxyliques
EP0749417A4 (fr) * 1994-03-11 1999-04-14 Smithkline Beecham Corp Composes de cyano et leur preparations
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
EP0796092A4 (fr) * 1994-12-23 1998-03-25 Smithkline Beecham Corp Dimeres de 3,3-(disubstitue)cyclohexan-one et composes apparentes
EP0800393A4 (fr) * 1994-12-23 1998-05-06 Smithkline Beecham Corp Monomeres de 4,4-(disubstitue)cyclohexan-1-one et composes correspondants
EP0799183A4 (fr) * 1994-12-23 1998-03-25 Smithkline Beecham Corp Monomeres de 3,3-(disubstitue)cyclohexan-1-one et composes apparentes
EP0800393A1 (fr) * 1994-12-23 1997-10-15 Smithkline Beecham Corporation Monomeres de 4,4-(disubstitue)cyclohexan-1-one et composes correspondants
EP0799183A1 (fr) * 1994-12-23 1997-10-08 Smithkline Beecham Corporation Monomeres de 3,3-(disubstitue)cyclohexan-1-one et composes apparentes
EP0796092A1 (fr) * 1994-12-23 1997-09-24 Smithkline Beecham Corporation Dimeres de 3,3-(disubstitue)cyclohexan-one et composes apparentes
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
WO1999011607A1 (fr) * 1997-08-28 1999-03-11 Lonza Ag Procede pour produire un 1-(3-cyclopentyloxy- 4-alcoxyphenyl)-4- oxocyclohexanecarbonitrile
US6300512B1 (en) 1997-08-28 2001-10-09 Lonza Ag Method for producing a 1-(3-cyclopentenyloxy-4-alkoxyphenyl)-4-oxocyclohexanecar-bonitrile
AU744361B2 (en) * 1997-08-28 2002-02-21 Lonza A.G. Method for producing a 1-(3-cyclopentenyloxy- 4-alkoxyphenyl)-4- oxocyclohexanecarbonitrile
EP1202955A2 (fr) * 1999-08-10 2002-05-08 SmithKline Beecham Corporation 4,4-diaryl cyclohexanes substitues en 1-4
EP1202955A4 (fr) * 1999-08-10 2004-02-11 Smithkline Beecham Corp 4,4-diaryl cyclohexanes substitues en 1-4
EP2281819A1 (fr) 2004-01-21 2011-02-09 Novartis AG Dérivés du benzimidazole ou du benzoxazole
EP3603634A1 (fr) 2004-05-18 2020-02-05 Novartis AG Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique
EP2292619A1 (fr) 2004-10-22 2011-03-09 Novartis AG Derivés de purin et leurs utilisation comme agonists d'adenosin-A2A-récepteur
EP2206499A1 (fr) 2004-11-02 2010-07-14 Novartis AG Derives de quinuclidine et leur utilisation en tant qu'antagonistes des recépteurs muscariniques m3
WO2006056471A1 (fr) 2004-11-29 2006-06-01 Novartis Ag Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2
EP2305659A1 (fr) 2004-11-29 2011-04-06 Novartis AG Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2
EP2253612A1 (fr) 2005-04-14 2010-11-24 Novartis AG Composés organiques
EP2270008A1 (fr) 2005-05-20 2011-01-05 Novartis AG 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones comme inhibiteurs de kinases lipidiques et/ou de la pi3 kinase
EP2292617A1 (fr) 2005-05-20 2011-03-09 Novartis AG Dérivés de 1,3-dihydro-imidazo[4,5-c]quinolin-2-one comme inhibiteurs de kinase lipidique et/ou de kinase pi3
EP2532677A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
EP2532679A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
WO2007071400A1 (fr) 2005-12-22 2007-06-28 Novartis Ag Derives de pyrazine en tant que bloqueur du canal sodique epithelial
EP2286813A2 (fr) 2006-01-31 2011-02-23 Novartis AG Utilisation de dérivés de naphthyridine comme medicaments
EP2322525A1 (fr) 2006-04-21 2011-05-18 Novartis AG Derives de purine comme d'agonistes des recepteurs de l'adenosine A2A
WO2007121920A2 (fr) 2006-04-21 2007-11-01 Novartis Ag Composés organiques
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
WO2008052734A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composés hétérocycliques en tant qu'agents anti-inflammatoires
EP2279777A2 (fr) 2007-01-10 2011-02-02 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéase à activation de canal
EP2332933A1 (fr) 2007-05-07 2011-06-15 Novartis AG Inhibiteurs du canal sodique épithélial
EP2444120A1 (fr) 2007-12-10 2012-04-25 Novartis AG Analogues d'Amiloride spirocyclique en tant que blocker d'ENaC
EP2520574A1 (fr) 2007-12-10 2012-11-07 Novartis AG Analogues d'Amiloride substitués sur la partie cyclique de la guanidine en tant que bloqueurs d'ENaC pour le traitement de maladies respiratoires
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
WO2009150137A2 (fr) 2008-06-10 2009-12-17 Novartis Ag Composés organiques
WO2010088335A1 (fr) 2009-01-29 2010-08-05 Novartis Ag Benzimidazoles substitués destinés au traitement d'astrocytomes
WO2011015652A1 (fr) 2009-08-07 2011-02-10 Novartis Ag Dérivés 3-hétéroarylméthyl-imidazo[1,2-b]pyridazin-6-yliques comme modulateurs de la tyrosine kinase c-met
WO2011018454A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composés hydrazone hétérocycliques et leurs utilisations pour traiter le cancer et l'inflammation
WO2011022439A1 (fr) 2009-08-17 2011-02-24 Intellikine, Inc. Composés hétérocycliques et leurs utilisations
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
WO2011050325A1 (fr) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques
EP2813227A1 (fr) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques
US11911371B2 (en) 2010-03-19 2024-02-27 Novartis Ag Pyridine and pyrazine derivative for the treatment of chronic bronchitis
WO2011113894A1 (fr) 2010-03-19 2011-09-22 Novartis Ag Dérivés de pyridine et de pyrazine pour le traitement de la mucoviscidose
USRE46757E1 (en) 2010-03-19 2018-03-20 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2845593A1 (fr) 2010-03-19 2015-03-11 Novartis AG Dérivé de pyridine et de pyrazine pour le traitement d'une maladie pulmonaire obstructive chronique
US9365552B2 (en) 2010-03-19 2016-06-14 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US10117858B2 (en) 2010-03-19 2018-11-06 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034091A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions à titre d'inhibiteurs de trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012035158A1 (fr) 2010-09-17 2012-03-22 Novartis Ag Dérivés de la pyrazine en tant que bloqueurs de l'enac
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
WO2013030802A1 (fr) 2011-09-01 2013-03-07 Novartis Ag Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
WO2013038362A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
WO2013038390A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Hétérocyclyle carboxamides n-substitués
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US9669032B2 (en) 2011-11-23 2017-06-06 Intellikine Llc Enhanced treatment regimens using mTOR inhibitors
WO2013140319A1 (fr) 2012-03-19 2013-09-26 Novartis Ag Forme cristalline d'un sel de succinate
WO2013149581A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
EP3964513A1 (fr) 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2014132220A1 (fr) 2013-03-01 2014-09-04 Novartis Ag Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2015162456A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162459A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162461A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2016011956A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
WO2016016822A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polythérapie
WO2020250116A1 (fr) 2019-06-10 2020-12-17 Novartis Ag Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie
WO2021038426A1 (fr) 2019-08-28 2021-03-04 Novartis Ag Dérivés de 1,3-phényl hétéroaryle substitués et leur utilisation dans le traitement d'une maladie

Also Published As

Publication number Publication date
JP3192424B2 (ja) 2001-07-30
KR100344712B1 (ko) 2002-12-05
JPH08507039A (ja) 1996-07-30
KR950700732A (ko) 1995-02-20
IL105218A0 (en) 1993-12-28

Similar Documents

Publication Publication Date Title
EP0636025B1 (fr) Composes efficaces dans le traitement de maladies allergiques ou inflammatoires
WO1993019750A1 (fr) Composes efficaces dans le traitement de maladies allergiques ou inflammatoires
US5602173A (en) Compounds useful for treating allergic and inflammatory diseases
AP519A (en) Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflamatory diseases.
US5449687A (en) 4-phenyl-1,2-cyclohexyl derivatives and anti-inflammatory compositions and methods thereof
WO1993019720A2 (fr) Composes
EP0727990B1 (fr) Composes, compositions et traitement d'allergies et de l'inflammation
WO1995009623A1 (fr) Composes et compositions antiallergiques et anti-inflammatoires et leurs utilisations
WO1995009836A1 (fr) Composes et compositions de cyanocyclohexane et leurs utilisations
US5861421A (en) 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
AU675640C (en) Compounds useful for treating allergic or inflammatory diseases
WO1995009837A1 (fr) Composes cyano
EP0799182A1 (fr) Dimeres 3,3-(disubstitue)cyclohexan-1-ol et composes apparentes
NZ299781A (en) 4-(substituted phenyl)-cyclohexanone derivatives and pharmaceutical compositions thereof
AU4688396A (en) 4,4-(disubstituted)cyclohexan-1-one monomers and related compounds
WO1996019977A1 (fr) Monomeres 3, 3-(disubstitues) cyclohexan-1-ol et composes correspondants
AU4527696A (en) 3,3-(disubstituted)cyclohexan-1-one monomers and related compounds
SI9300168A (sl) 3,4-disubstttuirani fenilcikloheksan-1-oni za zdravljenje bolezni, ki so v zvezi s pdeiv
EP0796092A1 (fr) Dimeres de 3,3-(disubstitue)cyclohexan-one et composes apparentes
EP0799187A1 (fr) Dimeres 4,4-(disubstitue)cyclohexane-1-carboxylate et composes apparentes
EP0796097A1 (fr) Monomeres 3,3-(disubstitues) cyclohexan-1-carboxylate et composes correspondants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: KZ

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
WWE Wipo information: entry into national phase

Ref document number: 2133337

Country of ref document: CA

Ref document number: 08313095

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 251176

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1019940703524

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1993907493

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993907493

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993907493

Country of ref document: EP